Catalog No.
Product Name
Application
Product Information
Citations
-
Antibiotic
A-54556A (ADEP 1) is an acyldepsipeptide antibiotic that primarily targets bacterial protein synthesis. It exhibits potent antibacterial activity against a diverse array of Gram-positive bacteria, making it a valuable tool for research on bacterial resistance and antibiotic efficacy. A-54556A is utilized in studies exploring mechanism of action and the development of novel antimicrobial agents. -
Antibiotic
Carbenicillin is a semi-synthetic penicillin antibiotic that primarily targets gram-negative bacteria through the inhibition of cell wall synthesis. It exhibits broad-spectrum antibacterial activity and is characterized by its relatively low toxicity towards plant tissues. Carbenicillin is commonly utilized in microbiological research and clinical applications to study bacterial growth and resistance mechanisms. -
Dianionic Cephem Antibiotic
Ceftibuten is a dianionic cephem antibiotic that exhibits potent antibacterial activity. It is effective in vitro against a variety of gram-negative bacteria and certain gram-positive pathogens. This compound is primarily used in research applications focused on antibiotic resistance and the mechanism of action of cephalosporins. -
Antibiotic
Eremomycin is a potent glycopeptide antibiotic that targets bacterial cell walls to inhibit growth. It exhibits significant antibacterial activity against Staphylococcus species and Bacillus subtilis ATCC6633, with minimal inhibitory concentrations ranging from 0.03 to 1.6 μg/mL. This compound is valuable in research applications focused on antibiotic resistance and the development of new antibacterial therapies. -
antibiotic
Spiramycin III is a macrolide antibiotic derived from Streptomyces ambofaciens, primarily targeting bacterial infections and Toxoplasma gondii. This compound exhibits notable antibacterial and antiparasitic activities, making it a valuable reagent for research applications focused on infectious diseases and parasitic challenges. Its versatile efficacy positions Spiramycin III as a critical tool in the study and treatment of various microbial infections. -
Antibacterial Agent
Avilamycin C is an avilamycin-type antibiotic that targets bacterial cell wall synthesis. It exhibits potent antibacterial activity, particularly against Gram-positive bacteria, making it valuable in research focused on antibiotic resistance and bacterial infections. This compound serves as a crucial tool for studies investigating mechanisms of action and the development of novel antibacterial therapies. -
Antibiotic
Showdomycin is an antibiotic targeting bacterial ribosomes, inhibiting protein synthesis. It is produced by Streptomyces in response to the IM-2 inducer. Showdomycin exhibits potent antibacterial activity, making it valuable for research on microbial resistance mechanisms and the development of new antibiotic therapies. -
Secondary Metabolite
Aurofusarin is a secondary metabolite derived from the fungus Fusarium graminearum, known as a significant pathogen affecting vital crops in temperate regions. This compound exhibits antifungal properties and plays a role in the ecological interactions of plant-fungal systems. Aurofusarin is utilized in research to explore plant-pathogen interactions and the biosynthetic pathways of secondary metabolites. -
Antibiotic
Thiocillin I is a thiopeptide antibiotic that exhibits potent antibacterial activity against Gram-positive bacteria. It has been shown to have minimum inhibitory concentration (MIC) values of 2 μg/mL against Staphylococcus aureus, 0.5 μg/mL against Enterococcus faecalis, 4 μg/mL against Bacillus subtilis, and 0.5 μg/mL against Streptococcus pyogenes. Thiocillin I is primarily used in research applications focused on bacterial resistance and antibiotic efficacy studies. -
Antimicrobial Agent
11β,13-Dihydrolactucin serves as an antimicrobial agent, demonstrating significant antibacterial and antifungal properties. Additionally, this compound exhibits various biological activities, including antioxidant, anti-inflammatory, and antitumor effects. Its versatile nature makes it a valuable reagent for research applications in microbiology and cancer studies. -
Antibiotic
Gilvocarcin V is an antibiotic that targets bacterial cells, exhibiting strong antibacterial activity. Isolated from Actinomycete, it also demonstrates anti-tumor properties, making it a valuable reagent for cancer research. Its dual functionality supports investigations into microbial resistance and tumor biology, contributing significantly to the understanding of these critical areas. -
Antibiotic
Clovibactin is an antibiotic that effectively targets drug-resistant bacterial pathogens with no detectable resistance. This compound functions by inhibiting cell wall synthesis, specifically targeting the pyrophosphate of peptidoglycan precursors. Its unique mechanism makes Clovibactin a valuable tool for researching antibiotic resistance and developing new therapeutic strategies against challenging bacterial infections. -
Antibiotic
(5S)-Neosamine C is an aminocyclic alcohol antibiotic that targets bacterial cell wall synthesis through its unique cyclized structure. This compound is derived from microbial secondary metabolites and serves as a key precursor in the biosynthesis of Neomycins. Its biological activity highlights its potential applications in antibiotic research and development. -
β-lactam Antibiotic
Cefoselis is a fourth-generation cephalosporin that functions as a β-lactam antibiotic, targeting bacterial cell wall synthesis. It demonstrates potent activity against a broad spectrum of Gram-positive and Gram-negative bacteria. Additionally, Cefoselis is capable of penetrating the blood-brain barrier, making it valuable for research applications related to central nervous system infections. -
Bacterial Inhibitor
Bacampicillin is a penicillin antibiotic that serves as a prodrug of ampicillin, designed to enhance oral bioavailability. It exerts its antibacterial activity through the inhibition of cell wall synthesis in susceptible bacteria. This compound is utilized primarily in microbiological research and studies targeting bacterial infections. -
Antibiotic
Norvancomycin hydrochloride is a glycopeptide antibiotic that targets bacterial cell wall synthesis. It demonstrates potent activity against various strains of Staphylococcus aureus and Staphylococcus epidermidis. This compound is primarily utilized in infection research to study antibiotic resistance and the mechanisms of bacterial pathogenicity. -
Antibiotic
4-Aminosalicylic acid hemicalcium acts primarily as an inhibitor of dihydrofolate reductase (DHFR) and serves as an effective antituberculous agent. This compound exhibits notable anti-inflammatory properties, making it a valuable tool for research into inflammatory bowel disease (IBD). Its oral bioavailability enhances its utility in various biochemical and pharmacological studies. -
Cephem Antibiotic
Cefcapene pivoxil is a prodrug form of Cefcapene, functioning as a third-generation cephalosporin antibiotic. It exhibits a broad spectrum of antibacterial activity, making it valuable for in vitro and in vivo studies of bacterial infections. Additionally, Cefcapene pivoxil has potential applications in research related to palmoplantar pustulosis (PPP). -
Antibiotic
Coformycin is a nucleoside antibiotic that primarily inhibits adenosine deaminase (ADA), an enzyme crucial for purine metabolism. This compound exhibits significant anti-tumor and anti-bacterial properties, making it valuable for research in cancer treatment and infectious disease. Coformycin's ability to modulate adenosine levels underscores its potential in therapeutic applications related to cellular proliferation and immune response. -
Antibiotic
L-Amoxicillin is a broad-spectrum antibiotic primarily targeting bacterial cell wall synthesis through inhibition of penicillin-binding proteins. It is widely utilized in clinical settings, often in conjunction with the β-lactamase inhibitor potassium clavulanic acid to enhance antimicrobial efficacy. Rigorous analysis methods for L-Amoxicillin have been developed, adhering to International Conference on Harmonization (ICH) guidelines, ensuring accuracy in quality assessment. Additionally, stability studies and stress testing have been conducted to determine the compound's robustness in various formulations, reinforcing its application in infection management. -
Antibiotic
Fosfomycin is a broad-spectrum antibiotic that irreversibly inhibits MurA, a crucial enzyme in bacterial cell wall synthesis. This compound effectively penetrates the blood-brain barrier and demonstrates significant antimicrobial activity against a variety of bacterial strains, including multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant (PDR) bacteria. Fosfomycin is widely used in research for studying bacterial resistance mechanisms and developing novel therapeutic strategies. -
Antibiotic
Cefoperazone dihydrate is a semisynthetic cephalosporin antibiotic targeting bacterial cell wall synthesis. It exhibits a broad spectrum of antibacterial activity against various Gram-positive and Gram-negative pathogens. This compound is utilized in microbiological research and clinical settings for the treatment of infections, making it valuable for studies on antibiotic resistance and therapeutic efficacy. -
Antibiotic
Pibrozelesin is a derivative of the antibiotic Duocarmycin B2, primarily targeting DNA cleavage. It demonstrates potent antitumor activity, inhibiting the proliferation of H69 cells with an IC50 of 1.9 μM. Upon activation by carboxyl esterase, Pibrozelesin induces DNA strand breaks, making it a valuable tool for cancer research and the study of DNA damage mechanisms. -
SARS-CoV-2 3CL Proteas Inhibitor
SARS-CoV-2 3CLpro-IN-13 is a highly effective inhibitor of the SARS-CoV-2 3CL protease, exhibiting an IC50 value of 21 nM. This compound demonstrates significant anti-coronavirus activity, making it a valuable tool for research focused on SARS-CoV-2 inhibition and antiviral drug development. It is suitable for studies investigating the biochemical mechanisms underlying coronavirus replication and the potential therapeutic strategies against SARS-CoV-2. -
SARS-CoV PLpro Substrate
Z-Arg-Leu-Arg-Gly-Gly-AMC is a synthetic peptide substrate specifically designed for the SARS-CoV PLpro enzyme. This compound facilitates the study of PLpro's proteolytic activity and its role in viral replication. It serves as a valuable tool for researchers investigating the molecular mechanisms of SARS-CoV and developing potential antiviral strategies. -
SARS-CoV-2 PLpro and Mpro Inhibitor
LY1 is a selective covalent inhibitor targeting the SARS-CoV-2 proteases PLpro and Mpro, demonstrating Kd values of 1.5 μM and 2.3 μM for Mpro C145A and PLpro C111A, respectively. It exhibits potent antiviral activity with IC50 values of 0.12 μM against Mpro and 0.99 μM against PLpro. Additionally, LY1 showcases high selectivity, distinguishing itself from other kinases, human proteases, and metalloenzymes, making it a valuable tool for research into SARS-CoV-2 protease inhibition. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-86 is an inhibitor targeting the methyltransferases nsp14 and nsp16 of SARS-CoV-2. This compound, a derivative of Andrographolide, demonstrates significant antiviral activity with low toxicity, evidenced by a predicted LD50 of 700 mg/kg. It serves as a valuable research tool for studying SARS-CoV-2 replication and may contribute to therapeutic strategies against COVID-19. -
SARS-CoV-2 Main Protease Inhibitor
X77 is a potent non-covalent inhibitor of the SARS-CoV-2 main protease (Mpro), displaying an affinity with a Kd value of 0.057 μM. This compound effectively disrupts the proteolytic activity of Mpro, crucial for viral replication. X77 is primarily utilized in research applications aimed at understanding SARS-CoV-2 biology and developing antiviral therapeutics. -
SARS-CoV 3CLpro Inhibitor
GRL-0496 is a potent inhibitor of SARS-CoV 3CLpro, functioning through targeting the viral protease essential for replication. It demonstrates significant enzyme inhibition with an IC50 of 30 nM and exhibits antiviral activity with an EC50 of 6.9 μM against SARS-CoV. This compound is valuable for research into antiviral therapies and the development of inhibitors aimed at addressing coronavirus infections. -
SARS-CoV-2 3CLpro Inhibitor
CCF0058981 is a noncovalent inhibitor targeting the SARS-CoV-2 3CL protease (3CLpro), with an IC50 of 68 nM. This compound also demonstrates activity against the SARS-CoV-1 3CLpro, exhibiting an IC50 of 19 nM. CCF0058981 shows promising antiviral efficacy and is a valuable tool for research applications focused on COVID-19 and coronavirus protease inhibition. -
SARS-CoV-2 Mpro Inhibitor
TKB245 is a potent inhibitor of the SARS-CoV-2 main protease (Mpro), demonstrating significant efficacy in preventing viral replication. This compound is effective in VeroE6 cells, making it a valuable tool for research on COVID-19 pathogenesis and therapeutics. Its role in protease inhibition provides insight into potential antiviral strategies against SARS-CoV-2. -
SARS-CoV-2 inhibitor
SARS-CoV-2-IN-39 is a SARS-CoV-2 inhibitor that functions by inhibiting the SKP2 protein and stabilizing BECN1. With an EC50 value of 1 μM, this compound demonstrates significant antiviral activity against SARS-CoV-2. It is suitable for research applications focusing on viral pathogenesis and the development of therapeutic strategies targeting coronavirus infections. -
SARS-CoV-2 Mpro Inhibitor
CDD-1845 is a potent non-covalent, non-peptide inhibitor of SARS-CoV-2 main protease (Mpro) with a Ki of 3 nM. This compound effectively inhibits various Mpro variants, including ΔP168, A173V, and ΔP168/A173V. CDD-1845 is intended for research applications focused on SARS-CoV-2 protease inhibition and therapeutic development against COVID-19. -
SARS-CoV-2 Inhibitor
Kobophenol A is an oligomeric stilbene that acts as a SARS-CoV-2 inhibitor by hindering the interaction between the ACE2 receptor and the S1-RBD, exhibiting an IC50 value of 1.81 μM. This compound effectively blocks viral infection in cellular models, with an EC50 of 71.6 μM. Additionally, Kobophenol A demonstrates inhibitory activity against partially purified rat brain protein kinase C (PKC), with an IC50 of 52 µM, making it a valuable tool for studies on viral pathogenesis and enzyme regulation. -
SARS-CoV-2 Inhibitor
PAV-104 is an identified inhibitor of SARS-CoV-2, targeting the nucleocapsid (N) protein. By disrupting the oligomerization of the nucleocapsid, PAV-104 effectively interferes with viral particle assembly, thereby impeding replication at a multiplicity of infection (MOI) of 0.01. This compound is a valuable tool for research into antiviral strategies and the mechanistic understanding of SARS-CoV-2 propagation. -
SARS-CoV-2 Inhibitor
MAT-POS-e194df51-1 is an orally active non-covalent inhibitor of the SARS-CoV-2 main protease (Mpro) with an IC50 of 37 nM. This compound exhibits significant cytotoxicity, demonstrated by EC50 values of 64 nM in A549-ACE2-TMPRSS2 cells and 126 nM in HeLa-ACE2 cells. MAT-POS-e194df51-1 can be utilized in research focusing on antiviral drug development and the pathway exploration of SARS-CoV-2 infection mechanisms. -
SARS-CoV-2 Main Protease Inhibitor
(Rac)-X77 is a potent non-covalent inhibitor of the SARS-CoV-2 main protease (Mpro). It demonstrates strong binding affinity with a Kd value of 0.057 μM, making it valuable for research into antiviral strategies against SARS-CoV-2. This compound is useful for studying protease inhibition mechanisms and developing therapeutic interventions targeting viral replication. -
SARS-CoV Inhibitor
SARS-CoV-2-IN-6 is a potent inhibitor of the SARS-CoV-2 3CL protease, exhibiting an IC50 value of 73 nM. This compound is critical for research focused on developing antiviral therapeutics against SARS-CoV-2 by targeting its main protease, which is essential for viral replication. Its efficacy makes it suitable for studies aimed at understanding the enzymatic mechanisms of the virus and the development of potential treatment strategies. -
SARS-CoV-2 3CL Protease Inhibitor
MK-7845 is a reversible covalent inhibitor targeting the 3CL protease of SARS-CoV-2, exhibiting an IC50 of 8.7 nM. This compound demonstrates potent antiviral activity, making it a valuable tool in the research of COVID-19 therapeutics. Its specificity for the 3CL protease supports investigations into the inhibition of viral replication and pathogenesis, facilitating the development of effective antiviral strategies. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-14 is a potent inhibitor of SARS-CoV-2, exhibiting an IC50 of 0.39 μM. This compound is a niclosamide analogue, demonstrating enhanced stability in human plasma and liver S9 enzyme assays compared to niclosamide. Due to these properties, SARS-CoV-2-IN-14 may offer improved bioavailability and prolonged half-life when administered orally, making it a valuable tool for studying antiviral mechanisms and developing therapeutic strategies against COVID-19. -
SARS-CoV-2 Mpro Inhibitor
GRL-1720 is a potent inhibitor of the SARS-CoV-2 main protease (Mpro), demonstrating an EC50 value of 15 µM. This compound exhibits significant anti-SARS-CoV-2 activity, making it a valuable tool for research related to coronavirus infection and therapeutics targeting viral replication. Its efficacy in inhibiting Mpro highlights its potential use in the development of antiviral strategies against SARS-CoV-2. -
HIV Protease Inhibitor
Palinavir is a potent inhibitor of HIV-1 and HIV-2 proteases, exhibiting an IC50 range of 0.5-30 nM. It demonstrates significant antiviral activity, making it valuable for research focused on HIV treatment strategies and drug development. Palinavir's mechanism of action targets the viral protease enzyme, disrupting the replication cycle of the virus and providing insights into HIV pathogenesis and therapeutic interventions. -
HIV-1 Protease Inhibitor
Lasinavir (CGP 61755) is a selective inhibitor of HIV-1 protease, exhibiting an IC50 value of 1 nM. This compound demonstrates significant antiviral activity against HIV-1, making it a valuable tool for studying HIV-1 infection and pathogenesis. Lasinavir is applicable in research focused on antiretroviral therapies and the mechanism of protease inhibition in viral replication. -
HIV Protease Inhibitor
L-689502 is a potent HIV protease inhibitor with an IC50 of 1 nM. This compound effectively disrupts the proteolytic activity of HIV-1 protease, thereby inhibiting viral replication. L-689502 is valuable for research into antiretroviral therapies and mechanisms of HIV resistance. -
Parasite Inhibitor
Betulonic acid, a naturally occurring triterpene, primarily targets parasite inhibition. It demonstrates significant antiparasitic activity along with anti-tumor and anti-inflammatory properties. Research applications include studies on its efficacy against various parasites, as well as exploration in cancer and inflammatory disease models. -
Antiviral Agent
3-Indoleacetonitrile is an indole derivative that acts as an antiviral agent, demonstrating significant activity against a wide range of influenza A viruses, herpes simplex virus type 1 (HSV-1), and vesicular stomatitis virus (VSV) in vitro. It has been shown to reduce lung virus titers and mitigate lung lesions in vivo, making it a valuable compound for studying antiviral mechanisms. Additionally, 3-Indoleacetonitrile enhances mitochondrial antiviral-signaling (MAVS) protein levels, indicating its role in reinforcing antiviral responses. This compound is suitable for research focused on viral infections, including influenza and COVID-19. -
HSV Replication Inhibitor
Tromantadine hydrochloride is an antiviral agent that inhibits the replication of herpes simplex virus types 1 and 2 (HSV-1 and HSV-2). As a derivative of Amantadine, it demonstrates significant antiherpetic activity and is primarily utilized in research applications focused on HSV pathogenesis and therapy development. This compound serves as a valuable tool in the study of viral infections and potential antiviral treatments. -
HSV Inhibitor
Isoborneol, a monoterpenoid alcohol, primarily targets herpes simplex virus type 1 (HSV-1) as a potent inhibitor. Exhibiting both antioxidant and antiviral properties, Isoborneol is utilized in research to explore its efficacy against viral infections. Its presence in the essential oils of various medicinal plants highlights its potential therapeutic applications in virology and pharmacology. -
HSV-1 Inhibitor
Soyasapogenol C is an oleanane-type triterpenoid that demonstrates significant antiviral activity against herpes simplex virus type 1 (HSV-1). With an IC50 value of 18.9 μM, it effectively inhibits viral replication, making it a valuable compound for research in virology and therapeutic development against HSV-1 infections. Its unique mechanism of action and biological potency position Soyasapogenol C as a candidate for further exploration in antiviral studies. -
HSV-1 Inhibitor
5-Nitrobarbituric acid functions as an inhibitor of herpes simplex virus type-1 (HSV-1), exhibiting an IC50 of 1.7 μM. This compound has demonstrated potential in virology research, particularly in studies aiming to understand and combat HSV-1 infections. Its utility in antiviral drug development positions it as a valuable tool for researchers exploring therapeutic strategies against herpes simplex viruses.
